Statement from Ilana Golant, Founder and CEO of the Food Allergy Fund
NEW YORK--(BUSINESS WIRE)--Today at the Food Allergy Fund Summit in New York City, Wade Shen, Director of Proactive Health at the Advanced Research Projects Agency for Health (ARPA-H), shared the agency's strategic priorities for advancing research and innovation to prevent, mitigate, and delay diseases, including food allergies and other urgent health challenges. He encouraged the event's attendees and the larger research community to engage with the agency as it helps to accelerate work on food allergies.
'On behalf of the Food Allergy Fund and our entire community, I extend my heartfelt thanks to Wade Shen and Dr. Jason Roos for affirming the agency's commitment to making allergic diseases a national health priority. Your leadership in driving research into the root causes of food allergies is essential to our mission: to prevent, treat, and ultimately cure this chronic disease. ARPA-H's bold, future-focused approach to funding transformative science reflects the growing recognition of food allergies as a serious and escalating public health issue.
'Food allergies are the canary in the coal mine for chronic disease and addressing them can unlock critical insights that can transform the future of public health. We are grateful for your partnership and dedication to advancing meaningful change for the millions of Americans affected by food allergies.'
About the Food Allergy Fund
The Food Allergy Fund (FAF) is the leading nonprofit dedicated to funding cutting-edge research to prevent, diagnose, and treat food allergies, a growing public health crisis affecting 10 percent of people in the United States and more than 300 million globally. Through innovative research grants and thought leadership summits, FAF is an incubator and convener, uniting scientists, policymakers, industry leaders, and entrepreneurs to drive breakthroughs. FAF's mission is to create a future where no one has to suffer from food allergies. To learn more, visit www.foodallergyfund.org.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Weight-loss drugs were said to be a game changer. Turns out the benefit might be thinner than thought
Common GLP-1 weight loss drugs - including Wegovy and Ozempic - may not work for everyone in a 'real-world' setting, Cleveland Clinic researchers said Tuesday. The reason is that patients may take lower dosages or discontinue their treatment, negatively impacting the ability to control blood sugar levels in those who are pre-diabetic. The findings may have implications for people considering using the drugs, that are taken by more than eight million Americans every year. They've offered an alternative to traditional and taxing weight loss methods, such as diets and fitness. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials,' Dr. Hamlet Gasoyan, a researcher with Cleveland Clinic, said in a statement. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' Gasoyan was the lead author of the study published on Tuesday in the Obesity Journal. 'Semaglutide has been extensively examined in robust clinical development programs, large real-world-evidence studies and has cumulatively over 33 million patient years of exposure,' a Novo Nordisk spokesperson told The Independent. 'Semaglutide's efficacy and safety have been extensively demonstrated in people with obesity/overweight with robust evidence for improving health outcomes. Semaglutide has demonstrated improvements in cardiovascular death, stroke, and myocardial infarction.' A request for comment from Eli Lilly was not immediately returned to The Independent. The study focuses on drugs with the active ingredients semaglutide and tirzepatide; they include the U.S. Food and Drug-administration approved type 2 diabetes medications Zepbound and Mounjaro. The authors studied their effects on weight loss and blood sugar regulation in a real-world setting. They noted that previous randomized clinical trials have shown the efficacy of those medications. The authors monitored the health of nearly 7,900 adults who were severely obese. Of those, more than 1,300 had pre-diabetes at the study's start and were at a higher risk for developing type 2 diabetes: a chronic condition that affects a person's ability to use insulin and keep blood sugar at normal levels. Participants took the shots between 2021 and 2023. The researchers sorted patients who discontinued their obesity medications into two groups: those who did it within just three months and by three months to a year. The study's follow-up period ended last December. The most common reasoning for discontinuation of treatment in the real-world setting was due to the steep cost of the drugs and insurance, side effects and shortages. Notably, since the study's, prices have started to fall. Of the participants, more than 20 percent discontinued their medications early and 32 percent discontinued their medications late. Furthermore, the authors noted than more than 80 percent had been on the lower dosages needed to sustain a therapeutic effect. For semaglutide, that's equal to or less than 1 milligram and equal to or less than 7.5 milligrams for tirzepatide. Following a year of treatment, the average weight reduction was 3.6 percent among participants who discontinued their treatment early, compared to 6.8 percent for those who discontinued their treatment late. But, those who did not discontinue treatment and were on the highest dosages necessary lost the most weight, at up to 13.7 percent with semaglutide and 18 percent with tirzepatide. Participants had higher odds of achieving 10 percent or greater weight reduction after one year of treatment if they did not discontinue their medications or did so late, were on the highest dosages needed for a therapeutic effect, received tirzepatide, and were women. Tracking the maintenance of blood sugar levels in those with pre-diabetes, the researchers said just a third of those who discontinued their treatment early experienced normal blood sugar levels compared to 41 percent who discontinued their treatment late and 67.9 percent who did not discontinue treatment. Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight compared to those who did not, their weight trajectories remained relatively stable. They said that would be the subject of additional research. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' explained Gasoyan.
Yahoo
40 minutes ago
- Yahoo
New federal Covid-19 vaccine policies are already keeping some people from getting shots
After federal health officials made abrupt changes to US Covid-19 vaccine recommendations for pregnant women last month, there's new confusion and uncertainty about who can get the shots — and some reports that patients were turned away when they tried to get vaccinated. Now, 30 health and medical organizations are pushing for continued access and insurance coverage for the vaccines. 'We are deeply concerned about the recently adopted HHS policy to no longer recommend COVID-19 vaccination during pregnancy,' wrote the organizations – including major professional groups for obstetricians, primary care providers, pediatricians, pharmacists and nurses – in an open letter. 'It is vital that we ensure that pregnant women continue to have access to this prevention tool so that they can protect themselves and their young infants, a vulnerable group who is not yet eligible for vaccination.' The letter calls on 'payers and insurers to continue making the COVID-19 vaccine available to pregnant people without undue utilization management or cost-sharing requirements,' even though the shots have been removed from the list of vaccines recommended by the US Centers for Disease Control and Prevention. Pregnant women who have Covid-19 are more likely to require care in the ICU or on a ventilator, or to die, the letter said, and they're at higher risk of complications such as cesarean birth, preeclampsia or eclampsia, and blood clots. Infants born after a Covid-19 infection also face increased risks. The letter comes two weeks after US Health and Human Services Secretary Robert F. Kennedy Jr. abruptly announced that the Covid-19 vaccine, which has shown to be safe and effective during pregnancy, would no longer be recommended for pregnant people. Leaders from the US Food and Drug Administration also recently outlined a new framework for the approval process for Covid-19 vaccines that could limit shots to older Americans and people at higher risk of serious Covid-19 infection. Experts immediately warned that these changes could create new barriers to vaccines for those who want them, including confusion around who is eligible and higher costs for patients if insurance no longer covers them. The American Pharmacists Association, which signed on to the open letter, said it has already received reports of patients being denied Covid-19 vaccines. Leigh Haldeman, 33, a nurse at Harborview Medical Center in Seattle who is pregnant, told CNN that she tried twice to get vaccinated last week and was turned away. 'Because of some complications I had during my first pregnancy, getting the vaccine now and getting that extra boost of immunity would be definitely important for me,' said Haldeman, who got her last shot in the fall of 2024. At two different pharmacies, she was told it is not recommended for pregnant women to receive the Covid-19 vaccine, based on new guidelines. She still hasn't been able to get the shot. Many doctors still strongly recommend Covid-19 vaccination during pregnancy. 'Despite the change in recommendations from HHS, the science has not changed,' the American College of Obstetricians and Gynecologists said in a statement. 'It is very clear that COVID-19 infection during pregnancy can be catastrophic and lead to major disability, and it can cause devastating consequences for families. The COVID-19 vaccine is safe during pregnancy, and vaccination can protect our patients and their infants after birth.' After an appointment last week, Haldeman agreed with her obstetrician's advice to get an additional Covid-19 shot during her pregnancy. Her first try was a Walgreens store where she had an appointment to get the vaccine. 'I went through the whole check-in process, and then as soon as the pharmacist saw that I was pregnant, they were like, 'We cannot give this to you,' ' she recounted. ' 'We're only giving it to immunocompromised people right now.' ' She said she asked whether she was considered immunocompromised because she's pregnant. Haldeman said the pharmacist responded that guidelines have changed, that it's not recommended and they wouldn't give it to her. She then called her primary care provider and obstetrician, but neither had the vaccine in stock. In past years, pharmacies have administered the majority of Covid-19 shots. A Walgreens spokesperson told CNN, 'We continue to closely monitor and review all federal and state guidance related to vaccines. As regulations and recommendations evolve, we remain committed to ensuring our pharmacy teams have the latest information to support patient care.' Haldeman said her obstetrician suggested trying another pharmacy. She called a Safeway and asked, 'I'm 25 weeks pregnant. My provider is recommending that I get this Covid booster. Are you able to give that to me?' The immediate answer was no. 'I'm under the impression from my provider that I need to get this,' she recalled saying. 'Pharmacies are the only people that appear to have it right now. What do I need to do to get this vaccine?' She said the pharmacist told her, 'The guidelines have changed as of last Friday. We can't give it to you.' The pharmacist suggested that Haldeman try getting a prescription for the vaccine from her provider so the pharmacy might be able to administer it. Her obstetrician wrote a vaccination prescription and sent it to the Safeway pharmacy, but when Haldeman visited the location at 7 p.m. the same day, she was told the pharmacy hadn't received the prescription. In a statement from a company spokesperson, Safeway parent company Albertsons told CNN, 'In accordance with recently updated CDC guidance, we adjusted our COVID-19 vaccination policies. Pregnant individuals with specific medical conditions that increase their risk of severe illness remain eligible for vaccination. We encourage all customers to consult with their healthcare providers for personalized advice.' The lack of clarity left Haldeman frustrated and uncertain about what to do next. 'I spent half my day on this. … Most people are probably not going to go to those lengths to get the vaccine. The more hoops that you make people jump through, less and less people are just going to get vaccinated,' Haldeman said. 'And we know that having Covid during pregnancy does terrible things to your placenta, and certainly reducing that risk is worth it. So it's very frustrating.' The American Pharmacists Association said in a news release that the updates to the Covid-19 recommendations 'do not appear to be based on the scientific evidence provided over the past few years. … COVID-19 vaccination during pregnancy has been proven safe and effective.' However, pharmacists 'may face consequences if they do not follow the Advisory Committee on Immunization Practices or CDC recommendations,' said Allison Hill, the association's director of professional affairs. 'HHS's and CDC's recent changes to the Covid-19 recommendations create barriers and confusion,' Hill said. HHS's unusual updates to the Covid-19 vaccine schedules were followed this week by a sweeping change to the CDC's Advisory Committee on Immunization Practices, the independent experts who typically guide the agency on its vaccine recommendations. Kennedy bypassed ACIP in making the Covid-19 changes and then said this week that he had dismissed the entire 17-member panel. On Wednesday, Kennedy announced eight new members to ACIP. The removal of the vaccine advisers sparked a swift backlash from health care providers and professional organizations. Dr. Tina Tan, president of the Infectious Diseases Society of America, another organization that signed the open letter, said that undermining the integrity of ACIP is 'completely unfounded' and has 'a significant negative impact on Americans of all ages.' The pharmacists association said Tuesday, 'It is highly concerning that removing 17 scientists overnight eliminates the historical knowledge, scientific training, and clinical expertise required to equip pharmacists and the public to make appropriate choices for health based upon the risk.' Since Kennedy announced changes to the Covid-19 vaccine schedule, doctors said they're worried about their patients and the future of vaccinations. 'We are worried about our patients in the future, who may be less likely to choose vaccination during pregnancy despite the clear and definitive evidence demonstrating its benefit,' Dr. Steven J. Fleischman, president of the American College of Obstetricians and Gynecologists, said in a statement. 'We are concerned about access implications and what this recommendation will mean for insurance coverage of the COVID-19 vaccine for those who do choose to get vaccinated during pregnancy. And as ob-gyns, we are very concerned about the potential deterioration of vaccine confidence in the future.' Studies have shown that infants who are born after a Covid-19 infection during pregnancy are at increased risk of stillbirth, respiratory distress and low birth weight. 'With maternal health being compromised, you have the risk for preterm delivery, babies that are born very small or potentially even fetal loss early on,' Dr. Flor Munoz-Rivas, an associate professor of pediatrics and infectious disease at Baylor College of Medicine, said last week. Dr. John Lynch, an associate medical director at the Harborview Medical Center and a colleague of Haldeman's, said Covid-19 vaccination during pregnancy also has benefits for the newborn. 'Vaccinating a mom leads to the protection of the baby when they don't have their own immune response,' Lynch said. Since the Covid vaccine is not available to babies younger than 6 months, vaccinating the mother may be the safest way for young children to gain some immunity. 'That first year of life remains the highest period of risk, and this is a vaccine-preventable disease,' Muñoz said. 'We can modify the outcomes for these babies through maternal vaccination and through infant vaccination.'
Yahoo
an hour ago
- Yahoo
eHealth Named to 2025 Fortune Best Workplaces in Texas by Fortune Media and Great Place To Work
AUSTIN, Texas, June 12, 2025 /PRNewswire/ -- eHealth, Inc. (Nasdaq: EHTH) ( a leading online private health insurance marketplace, has been named as one of this year's Best Workplaces in Texas by Great Place To Work and Fortune magazine. eHealth is proud to be named to this prestigious list, coming in at No. 25. To be selected, eHealth surpassed rigorous benchmarks and has established itself as one of the best workplaces in Texas. To determine the Fortune Best Workplaces in Texas™ List, Great Place To Work surveyed nearly 116,000 employees at eligible companies via its proprietary platform. Companies were ranked based on their ability to offer consistently positive experiences, building trust with leaders, colleagues, and the overall organization. "While we're proudly headquartered in Austin, our workplace excellence spans nationwide through our remote-first approach," says Jana Brown, eHealth's Chief Human Resources Officer. "This recognition places us among an elite group of companies that excel in the foundational elements that drive true workplace excellence. Our team members across the country embody our values daily, proving that when you prioritize people and create intentional connection, exceptional results follow—regardless of where the work gets done." The Best Workplaces in Texas list is highly competitive. Survey responses reflect a comprehensive picture of the workplace experience. Honorees were rewarded based on their ability to deliver positive outcomes for employees regardless of role or status within the organization. To be eligible for the list, companies must be Great Place To Work Certified™, have at least 10 U.S. employees, and be headquartered in Texas. "Congratulations to the Fortune Best Workplaces in Texas," says Michael C. Bush, CEO at Great Place To Work. "These companies prove that prioritizing people leads to better performance, and that leaders who invest in their people are rewarded with more sustainable and profitable businesses." About eHealth (NASDAQ: EHTH) We're Matchmakers. For over 25 years, eHealth has helped millions of Americans find the healthcare coverage that fits their needs at a price they can afford. Consumers can visit our health insurance marketplace at or call us to speak with a licensed insurance agent at 1-833-964-1202. As a leading independent licensed insurance agency and advisor, eHealth offers access to over 180 health insurers, including national and regional companies. For more information, visit or follow us on LinkedIn, Facebook, Instagram, and X. Open positions can be found on our career page. eHealth media inquiries: pr@ About the Fortune Best Workplaces in Texas Great Place To Work selected the 2025 Fortune Best Workplaces in Texas by surveying 1.3 million employees in the U.S., representing companies that collectively employ more than 8.4 million U.S. workers. Of those responses, nearly 116,000 were received from employees at companies that were eligible for the 2025 Fortune Best Workplaces in Texas List, and these rankings are based on their feedback. To be eligible, companies must be Great Place To Work Certified™, have at least 10 U.S. employees, and be headquartered in Texas. Read the full methodology. To get on this list next year, start here. About Great Place to Work As the global authority on workplace culture, Great Place To Work brings more than three decades of groundbreaking research and data to help every place become a great place to work for all. Its proprietary platform and Great Place To Work Model™ help companies evaluate the experience of every employee, with exemplary workplaces becoming Great Place To Work Certified or receiving recognition on its coveted Best Workplaces™ lists. Follow Great Place To Work on LinkedIn, Twitter, and Instagram or visit and sign up for the newsletter to learn more. About Fortune Fortune upholds a legacy of award-winning writing and trusted reporting for executives who want to make business better. Independently owned, with a global perspective and digital agility, Fortune tells the stories of a new generation of innovators, builders, and risk-takers. Online and in print, Fortune measures corporate performance through rigorous benchmarks and holds companies accountable. Fortune creates communities by convening true thought leaders and iconoclasts — those who shape industry, commerce and society — through powerful and prestigious lists, events, and conferences, such as the iconic Fortune 500, the CEO Initiative and Most Powerful Women. For more information, visit View original content to download multimedia: SOURCE eHealth, Inc.
